Puma Biotechnology Inc CEO Alan Auerbach Sells 41,396 Shares
Alan Auerbach, President, CEO, and 10% Owner of Puma Biotechnology Inc (NASDAQ:PBYI), executed a sale of 41,396 shares in the company on January 3, 2024, according to a recent SEC Filing.
Puma Biotechnology Inc is a biopharmaceutical company that focuses on the development and commercialization of innovative products to enhance cancer care. The company aims to acquire and develop novel therapeutics for the treatment of various forms of cancer. Its portfolio includes targeted treatments that address specific oncogenic drivers and its lead product is a kinase inhibitor used in the treatment of breast cancer.
Over the past year, the insider has sold a total of 102,094 shares and has not made any purchases. The recent transaction is part of a series of sales by the insider, contributing to the 18 insider sells that have occurred over the past year. There have been no insider buys in the same period.
On the date of the sale, shares of Puma Biotechnology Inc were trading at $4.49, giving the company a market capitalization of $223.11 million. The stock's price-earnings ratio stands at 58.63, which is above both the industry median of 32.46 and the company's historical median price-earnings ratio.
The stock's price relative to the GuruFocus Value (GF Value) indicates that Puma Biotechnology Inc is significantly overvalued. With a share price of $4.49 and a GF Value of $3.42, the price-to-GF-Value ratio is 1.31. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which factors in historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
